Kura Oncology (NASDAQ:KURA) Price Target Cut to $11.00 by Analysts at Barclays

Kura Oncology (NASDAQ:KURA - Free Report) had its price objective reduced by Barclays from $32.00 to $11.00 in a research report released on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other research firms also recently issued reports on KURA. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Monday, April 28th. StockNews.com raised Kura Oncology from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. UBS Group reduced their price target on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and an average target price of $23.89.

Kura Oncology Trading Down 0.3 %

Shares of NASDAQ KURA traded down $0.02 during midday trading on Friday, reaching $6.47. 1,635,415 shares of the stock were exchanged, compared to its average volume of 1,159,940. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $23.48. The business has a 50-day simple moving average of $6.73 and a two-hundred day simple moving average of $9.52. The company has a market capitalization of $522.63 million, a price-to-earnings ratio of -2.74 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analysts' expectations of $39.08 million. As a group, equities research analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Virtus ETF Advisers LLC increased its stake in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after purchasing an additional 3,061 shares during the period. Pallas Capital Advisors LLC bought a new position in Kura Oncology during the 1st quarter worth $66,000. Flower City Capital acquired a new stake in shares of Kura Oncology during the first quarter worth $79,000. Harbor Advisors LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at about $87,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Kura Oncology in the fourth quarter valued at about $90,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.